Viekira Pak Induced Fatal Lactic Acidosis: A Case Report of an Unusual Side Effect

Abstract EN

Viekira Pak is a new direct-acting antiviral agent that has an excellent efficacy in treating patients with chronic HCV.

FDA released a safety warning that Viekira Pak can cause serious liver injury mostly in patients with underlying advanced liver disease.

We report the first case of fatal lactic acidosis presenting 3 days after initiating therapy with Viekira Pak.

Although it is very hard to precisely determine the cause of lactic acidosis, our case highlights an unusual side effect that ensued after starting the medication.

Given the complexity of drug-drug interactions that can happen with the new direct-acting antiviral agents and the paucity of data regarding coadministration and methods of monitoring, a thorough review should be pursued prior to initiating these medications.